Multicentric initial experience with the use of the Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis
Conclusions Implementing a PIPAC program in association with systemic chemotherapy is feasible and is associated with a risk of postoperative morbidity, even in teams highly experienced in PC management and requires a learning curve in patient selection. Teaser PIPAC is a recent approach for intraperitoneal chemotherapy with promising results for patients with PC. Implementing a PIPAC program in association with systemic chemotherapy is associated with a risk of postoperative morbidity, even in teams highly experienced in PC management.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More News: Asbestosis | Cancer & Oncology | Carcinoma | Chemotherapy | Constipation | Gastroenterology | Learning | Mesothelioma | Ovarian Cancer | Ovaries | Pain | Pain Management | Peritoneal Cancer | Surgery | Universities & Medical Training